Filtered By:
Source: Current Medical Research and Opinion
Drug: Pradaxa
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 28 results found since Jan 2013.
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population.
CONCLUSIONS: Among the DOACs in the study, only apixaban is associated with a significantly lower risk of stroke/SE and major bleeding and lower related medical costs compared to warfarin.
PMID: 28635338 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 22, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
CONCLUSION: QD NOACs prevented a significant number of strokes and caused no significant increase in MBs compared to BID NOACs which leads to significant net cost savings for NVAF patients in the US.
PMID: 30265159 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 29, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis
CONCLUSIONS: This real-world analysis showed DOACs to be associated with lower risk of stroke/SE and major bleeding, and lower medical costs compared to warfarin. Among them, only apixaban appears to be associated with a significantly lower risk of all three outcomes collectively: stroke/SE, major bleeding, and lower related medical costs compared to warfarin.PMID:35993487 | DOI:10.1080/03007995.2022.2115772
Source: Current Medical Research and Opinion - August 22, 2022 Category: Research Authors: Alpesh Amin Allison Keshishian Dionne M Hines Oluwaseyi Dina Hannah Le Lisa Rosenblatt Xianchen Liu Qisu Zhang Lien Vo Source Type: research
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
CONCLUSIONS: In this study using US Medicare real-world data, dabigatran was found to dominate rivaroxaban. The analyses were limited by the short follow-up period of the real-world data and results may not be generalizable to other patient populations.
PMID: 28862479 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 3, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of medication adherence on risk of ischemic stroke, major bleeding, and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants.
CONCLUSION: Adherence to NOACs for both 6 months and continued prolong use (up to 12-months) was associated with a reduction in IS and DVTPE risk, but did not substantially increase risk of MB. Further studies on newer, individual NOACs and older population are warranted.
PMID: 29334815 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 18, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study).
CONCLUSIONS: A mixed intervention, consisting of patient education and a simple calendar reminder of drug intake, is an effective strategy to improve dabigatran therapeutic adherence in patients with NVAF. The percentage of adherence with dabigatran was high.
PMID: 29384410 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 1, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
CONCLUSIONS: NVAF patients using different DOACs had different characteristics, including stroke and bleeding risks. Use of rivaroxaban, compared to apixaban was associated with significantly greater risk of bleeding-related readmissions across two database claims analyses.
PMID: 26652179 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 18, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Improved persistence with non-vitamin K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience.
CONCLUSIONS: Persistence with NOAC drugs in patients with AF appears to be superior to warfarin. If continued long-term, this alone will be of clinical importance in the prevention of stroke and death.
PMID: 27463735 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 29, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research
Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban.
CONCLUSION: NOACs may provide alternative treatment options in areas of unmet need, and numerous studies are underway to assess their benefit-risk profiles in these settings.
PMID: 29672182 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - April 21, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Real-life behaviour of direct oral anticoagulants in a Spanish cohort with nonvalvular atrial fibrillation: Refase Registry.
CONCLUSION: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose).
PMID: 31335222 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation and Valvular Heart Disease.
CONCLUSIONS: NOACs had a comparable risk of ischemic stroke and bleeding in patients with AF and VHD, and reduced the risk of venous thromboembolism, intracranial hemorrhage, and mortality, compared to warfarin. Therefore, NOAC is an effective and safe alternative to warfarin in these patients.
PMID: 33538623 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research
